A pharmacological profile of somapacitan for the treatment of growth hormone deficiency

Continued somapacitan therapy in clinical trials in children with GHD has shown ongoing catch-up growth while having a similar safety profile to daily growth hormone. However, it will be important to capture real world data demonstrating ongoing safety, efficacy, and adherence in children and adults receiving somapacitan and other LAGH therapies.